Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 36-42 , January 2008

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index

  • Julie M. Vose

      Affiliations

    • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
    • Corresponding Author InformationCorrespondence and reprint requests: Julie M. Vose, MD, Section of Hematology/Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680; Tel: 402-559-3848; Fax: 402-559-6520.
    • ,
  • Philip J. Bierman

      Affiliations

    • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Fausto R. Loberiza

      Affiliations

    • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • James C. Lynch

      Affiliations

    • Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Gregory R. Bociek

      Affiliations

    • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • Dennis D. Weisenburger

      Affiliations

    • Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
    • ,
  • James O. Armitage

      Affiliations

    • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska

Received 17 September 2006 ,Accepted 17 June 2007.

References 

  1. McLaughlin P, Fuller LM, Velasquez WS, et al. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol. 1987;5:867–874
  2. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71–75
  3. Czuczman MS, Weaver R, Alkuzeny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab and CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716
  4. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  5. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–147
  6. Bierman PJ, Vose JM, Anderson JR, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:445–450
  7. Rohatiner AZ, Freedman A, Nadler L, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol. 1994;5(Suppl 2):143–146
  8. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325–3333
  9. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood. 1995;86:3257–3262
  10. Shouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–3927
  11. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization (WHO) classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Arlie House, Virginia. November 1997 J Clin Oncol. 1999;17:3835–3849
  12. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index (FLIPI). Blood. 2004;104:1258–1265
  13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253
  14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  15. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–202
  16. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452
  17. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026
  18. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008
  19. van Oers MHJ, Klasa Richard, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–3301
  20. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  21. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and I-131-tositumomab (Bexxar) after rituximab. J Clin Oncol. 2005;23:712–719
  22. Gordon LI, Witzig T, Molina A, et al. Yttrium 90–labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5:98–101
  23. Koc ON, Redfern C, Wiernik PH, et al. Active immunotherapy with FavId (Id/KLH) following rituximab induction: long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma. [abstract] ASHA. 2006;108:691a
  24. Witzig TE, Vose JM, Kaplan HP, et al. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. [abstract] Blood. 2006;108:160a
  25. Vose JM, Bierman PJ, Lynch JC, et al. Autologous transplant event-free survival (EFS) following failure of CHOP-rituximab (CHOP-R) for diffuse large B-cell lymphoma (DLBCL) is the same as the EFS following failure of CHOP alone. [abstract] Blood. 2004;104:890a

PII: S1083-8791(07)00458-2

doi: 10.1016/j.bbmt.2007.06.016

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 36-42 , January 2008

Article Tools

* Image Usage & Resolution